US FDA Grants Orphan Drug Designation to Gracell’s FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy, GC012F to Treat Multiple Myeloma.
Synopsis: The FDA granted orphan drug designation to GC012F, a novel chimeric antigen receptor T-cell therapy for the treatment of relapsed or…